
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Net Debt 2011-2026 | SWAV
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 407 M | -131 M | -77.5 M | -43.5 M | -125 M | -24.6 M | -51.9 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 407 M | -131 M | -6.68 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
-4.85 M | $ 2.11 | - | $ 3.29 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 10.42 | - | $ 1.41 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 3.91 | - | $ 828 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 37.41 | - | $ 1.16 B | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 12.6 | - | $ 1.89 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 8.38 | - | $ 602 M | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.96 | 1.02 % | $ 148 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 69.79 | - | $ 103 B | ||
|
Establishment Labs Holdings
ESTA
|
174 M | $ 63.48 | - | $ 1.88 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.19 | - | $ 1.33 M | ||
|
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.65 | -8.13 % | $ 35.4 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.33 | - | $ 21.5 M | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 11.03 | - | $ 298 M | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
LivaNova PLC
LIVN
|
-282 M | $ 61.43 | - | $ 3.35 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.42 | 0.22 % | $ 121 M | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 13.43 | - | $ 868 M | ||
|
MiMedx Group
MDXG
|
-148 M | $ 4.41 | - | $ 652 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Abbott Laboratories
ABT
|
1.65 B | $ 109.95 | - | $ 191 B | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 9.81 | - | $ 351 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 261.24 | - | $ 7.37 B | ||
|
Insulet Corporation
PODD
|
468 M | $ 224.66 | - | $ 15.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.01 | - | $ 694 M | ||
|
Profound Medical Corp.
PROF
|
-7.36 M | $ 5.71 | - | $ 180 M | ||
|
AxoGen
AXGN
|
15.2 M | $ 32.84 | - | $ 1.51 B | ||
|
Align Technology
ALGN
|
-925 M | $ 169.45 | - | $ 12.7 B | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 32.76 | - | $ 4.88 K | ||
|
AVITA Medical
RCEL
|
29.1 M | $ 4.62 | 5.0 % | $ 129 M |